Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518303 | 0.84 | BLM (0.46) | BLMLMNAMAPTHTTAHR | |
| SCHEMBL994489 | 0.76 | MAPT (0.44) | LMNAMAPTCYP1A2CYP3A4TDP1 | |
| SCHEMBL30338444 | 0.76 | APEX1 (0.34) | MAPTTDP1MEN1NPC1RAB9A | |
| SCHEMBL90933 | 0.76 | MMP12 (0.36) | LMNAMAPTHTTCYP1A2MEN1 | |
| SCHEMBL1046470 | 0.76 | ALOX5 (0.30) | — | |
| SCHEMBL3331065 | 0.76 | CYP3A4 (0.55) | MAPTMAOBCYP3A4RAB9A | |
| SCHEMBL5373991 | 0.76 | ALOX5 (0.30) | — | |
| SCHEMBL6490064 | 0.76 | ADRA2A (0.36) | PNMT | |
| SCHEMBL11816254 | 0.75 | AHR (0.43) | BLMLMNAMAPTHTTAHR | |
| SCHEMBL12188934 | 0.72 | PARP1 (0.41) | MAPTCYP1A2CYP3A4MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738632-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-08-22 | — | — | US | disclosed |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-9512110-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2016-12-06 | — | — | US | disclosed |
| EP-2291369-B1 | BENZODIOXINYL SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-20150080434-A1 | PHENYL AND BENZODIOXINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-19 | — | — | US | disclosed |
| US-8916600-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2014-12-23 | — | — | US | disclosed |
| EP-2620435-A1 | Phenyl and benzodioxinyl substituted indazole derivatives | Astrazeneca AB (SE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120302617-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2012-11-29 | — | — | US | disclosed |
| US-8211930-B2 | Phenyl and benzodioxinyl substituted indazoles derivatives | ASTRAZENECA AB (SE) | 2012-07-03 | — | — | US | disclosed |
| WO-2011061527-A1 | COMBINATIONS COMPRISING A GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | WO | disclosed |
| US-20100087489-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302617-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | CYP3A5, CYP4X1, CYP3A7 | BLM 1314/4885LMNA 1746/4885MAPT 3267/4885 |
| US-20150080434-A1 | PHENYL AND BENZODIOXINYL SUBSTITUTED INDAZOLES DERIVATIVES | CYP3A5, ABCB1, CYP4X1 | BLM 995/4885LMNA 1359/4885MAPT 3351/4885 |
| US-20100087489-A1 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives | CYP3A5, ABCB1, CYP4X1 | BLM 995/4885LMNA 1359/4885MAPT 3351/4885 |
| US-20170081315-A1 | Phenyl and benzodioxinyl substituted indazoles derivatives | CYP3A5, ABCB1, CYP4X1 | BLM 995/4885LMNA 1359/4885MAPT 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.